| Previous Close | 2.05 |
| Open | 2.08 |
| Bid | 2.00 x 500 |
| Ask | 2.16 x 15000 |
| Day's Range | 2.03 - 2.08 |
| 52 Week Range | 1.81 - 3.15 |
| Volume | 592,509 |
| Avg. Volume | 1,308,632 |
| Market Cap | 324.72M |
| Beta | 2.96 |
| PE Ratio (TTM) | -11.40 |
| EPS (TTM) | -0.18 |
| Earnings Date | May 4, 2017 - May 8, 2017 |
| Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.75 |
- Zacks•3 days ago
Geron's (GERN) Imetelstat Progressing Well, Setbacks Concern
Geron Corporation's (GERN) telomerase inhibitor, imetelstat, is being evaluated in two late stage studies. The candidate is progressing well in the Janssen sponsored studies.
- Zacks•7 days ago
Geron (GERN) Q2 Loss Narrows, Sales Miss Estimates, Stock Up
Geron Corporation (GERN) reported narrower-than-expected loss in Q2 while sales missed estimates. Shares were up in after-hours trading.
- Associated Press•7 days ago
Geron reports 2Q loss
On a per-share basis, the Menlo Park, California-based company said it had a loss of 4 cents. The drugmaker posted revenue of $174,000 in the period. In the final minutes of trading on Wednesday, the company's ...
